Alkyl dihydroquinoline sulfonamide compounds
The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
1. A compound of Formula I, or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is selected from —CH 2 —CF 3 , —CH 2 —CH 2 —CF 3 , —CH 2 —CH 2 —CH 2 —CF 3 , —CH 2 —CH(CH 3 )—CF 3 , —CH 2 —CF 2 —CF 3 , —CH 2 —C(CH 3 ) 2 —CF 3 , —C(CH 3 ) 2 —CH 2 —CF 3 , —CF 2 —CH 2 —CF 3 , or —CH 2 —CH 2 —CHF 2 ;
R 2 is H, halo, C 1-6 alk, or C 1-6 haloalk;
R 3 is C 1-6 alk, C 1-6 haloalk, —O—C 1-6 alk, or CN;
R 4 is a 5- to 6-membered heteroaryl;
Each of R 6 and R 7 is hydrogen; and
Each of R 5a ; R 5b ; R 5c ; R 5d ; and R 5e is independently hydrogen or halo.
2. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 1 having the formula:)
or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof.
10. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof.
12. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof.
13. The pharmaceutically acceptable salt of the compound according to claim 2 .
14. The pharmaceutically acceptable salt of the compound according to claim 3 .
15. The pharmaceutically acceptable salt of the compound according to claim 4 .
16. The pharmaceutically acceptable salt of the compound according to claim 5 .
17. The pharmaceutically acceptable salt of the compound according to claim 6 .
18. The pharmaceutically acceptable salt of the compound according to claim 7 .
19. The pharmaceutically acceptable salt of the compound according to claim 8 .
20. The pharmaceutically acceptable salt of the compound according to claim 9 .
21. The pharmaceutically acceptable salt of the compound according to claim 10 .
22. The pharmaceutically acceptable salt of the compound according to claim 11 .
23. The pharmaceutically acceptable salt of the compound according to claim 12 .
24. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 2 , and a pharmaceutically acceptable carrier.
25. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 3 , and a pharmaceutically acceptable carrier.
26. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 4 , and a pharmaceutically acceptable carrier.
27. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 5 , and a pharmaceutically acceptable carrier.
28. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 6 , and a pharmaceutically acceptable carrier.
29. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 7 , and a pharmaceutically acceptable carrier.
30. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 8 , and a pharmaceutically acceptable carrier.
31. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 9 , and a pharmaceutically acceptable carrier.
32. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 10 , and a pharmaceutically acceptable carrier.
33. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 11 , and a pharmaceutically acceptable carrier.
34. A pharmaceutical composition comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 12 , and a pharmaceutically acceptable carrier.
35. A method of treating a condition treatable by inhibition of sodium channels, wherein the condition is selected from pain, cough, or itch, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
36. The method according to claim 35 ; wherein the condition is pain, which is selected from chronic pain, acute pain, neuropathic pain, pain associated with rheumatoid arthritis, pain associated with osteoarthritis, or pain associated with cancer.
37. The method according to claim 35 ; wherein the condition is cough, which is selected from post viral cough, viral cough, or acute viral cough.